
EPIC JNJ-80202135
Clinical Study
JNJ-80202135 is a clinical study by Janssen Research & Development to determine the efficacy and safety of Nipocalimab vs. Efgartigimod for patients with Generalized Myasthenia Gravis.
This is a a randomized, open-label, phase 3b, interventional trial which includes within class switching from Efgartigimod to Nipocalimab.
To qualify, participants generally must include:
-
Age: 18 - 74 years
-
Diagnosis:
Myasthenia Gravis
-
Patients must be AChR antibody positive
-
Patients test positive for generalized Myasthenia Gravis, ocular symptoms must account for less than 50% of symptoms
-
MG-ADL score greater than 5
-
Patients must be on a stable dosing regimen prior to screening
Standard .Standard Clinical Study Inquiry Form to be inserted below this information like the other study pages currently online.
